KPIs & Operating Metrics(New)

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Twist Bioscience (TWST) Acquisitions (2021)

Twist Bioscience has reported Acquisitions over the past 1 years, most recently at $8.2 million for Q4 2021.

Quarterly Acquisitions changed N/A to $8.2 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Sep 2022, changed N/A year-over-year, with the annual reading at $8.2 million for FY2022, 1589.44% up from the prior year.
Acquisitions was $8.2 million for Q4 2021 at Twist Bioscience, up from $483000.0 in the prior quarter.
Over five years, Acquisitions peaked at $8.2 million in Q4 2021 and troughed at $483000.0 in Q2 2021.